logo

For the Inventor, By the Inventor

Venissieux, France

Flamel Technologies


USPTO Granted Patents = 50

% Expired Patents = 40.0



Trademarks = 1

Forward Citations = 1,396

Loading Chart...
Loading Chart...

45 inventors (with patents filed for the assignee):

goldMedal Remi Meyrueix (11 out of 17 patents)

silverMedal Florence Guimberteau (9 out of 24 patents)

bronzeMedal You-Ping Chan (9 out of 41 patents)

4.  Gerard Soula (9 out of 61 patents)

5.  Catherine Castan (9 out of 15 patents)

6.  Gérard Soula (8 out of 14 patents)

7.  Rémi Meyrueix (7 out of 10 patents)

8.  Olivier Breyne (7 out of 22 patents)

9.  Nathan J Bryson (6 out of 8 patents)

10.  Olivier Soula (5 out of 33 patents)

11.  Florence Nicolas (5 out of 5 patents)

12.  Alain Constancis (4 out of 10 patents)

13.  Rémi Soula (4 out of 6 patents)

14.  Gerard Mignani (4 out of 41 patents)

15.  Gilles Hugues Tapolsky (4 out of 4 patents)


Core Competencies:
Microcapsules
Modified Release
Oral Formulations
Therapeutic Applications
Anti-Misuse
Prolonged Release
Pharmaceutical Compositions
Colloidal Suspensions
Polyamino Acids
Galenical Forms
Aerosol Compositions
Biomaterials

50 patents:

1. 9233993 - N-phosphonomethylglycine guanidine derivative salts (2016-01-12),
2. 9023400 - Prolonged-release multimicroparticulate oral pharmaceutical form (2015-05-05),
3. 8895063 - Oral dosage form comprising an antimisuse system (2014-11-25),
4. 8821935 - Microcapsules with modified release of active principles with low solubility for oral delivery (2014-09-02),
5. 8734850 - Oral medicinal product with modified release of at least one active principle in multimicrocapsular form (2014-05-27),
6. 8679540 - Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications (2014-03-25),
7. 8652529 - Anti-misuse microparticulate oral pharmaceutical form (2014-02-18),
8. 8652523 - Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with slow solubility (2014-02-18),
9. 8507003 - Compressed tablets comprising microcapsules with modified release (2013-08-13),
10. 8481019 - Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof (2013-07-09),
11. 8445023 - Anti-misuse microparticulate oral pharmaceutical form (2013-05-21),
12. 8293255 - Polyglutamic acids functionalised by histidine derivatives and hydrophobic groups and the uses thereof, in particular for therapeutic purposes (2012-10-23),
13. 8236353 - Self-precipitating pharmaceutical formulations for the modified release of an active principle (2012-08-07),
14. 8206744 - Branched polyamino acids functionalized with hydrophobic groups, and applications thereof particularly therapeutic applications (2012-06-26),
15. 8197850 - Medicine based on anti-hyperglycaemic microcapsules with prolonged release and method for preparing same (2012-06-12),
Flamel Technologies, headquartered in Venissieux, France, specializes in the development and manufacturing of innovative pharmaceutical formulations. The company focuses on advanced technologies such as microencapsulation and modified release systems, which enhance the therapeutic efficacy of oral medications. Flamel's expertise extends to creating formulations that address anti-misuse and prolonged release, catering to diverse therapeutic applications. Their commitment to improving drug delivery systems positions them as a key player in the pharmaceutical industry.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

50 Patents

#1 in Venissieux

#475 in France

#13,981 in the World

Venissieux, FR
Venissieux, France

Flamel Technologies

Forward Citations = 1,396

45 inventors:

goldMedal Remi Meyrueix (11 out of 17 patents)

silverMedal Florence Guimberteau (9 out of 24 patents)

bronzeMedal You-Ping Chan (9 out of 41 patents)

4.  Gerard Soula (9 out of 61 patents)

5.  Catherine Castan (9 out of 15 patents)

Please report any incorrect information to [email protected]
Loading…